Chief Science Officer · Keros Therapeutics, Inc. · Common Stock
Side
SELL
Value
$63K
Shares
3,873
Price
$16.35
Executed
Feb 18, 2026
Disclosed
Feb 20, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 18 executedFeb 20, 2026 disclosed
KROS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Lerner Lorena Raquel filed this Form 4 reporting a open-market sale of KROS on Feb 18, 2026. It became public on Feb 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Science Officer
Lerner Lorena Raquelcik:0002081359
Issuer
Keros Therapeutics, Inc.cik:0001664710
Revision history · 0
No field has changed since this record was first ingested.
